Immutep (ASX:IMM) has announced that data from the TACTI-002 Phase II trial of eftilagimod alpha in combination with pembrolizumab for 2nd line PD-X refractory non-small cell lung cancer patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023.
The study showed that 83% of patients experienced deceleration or shrinkage of target lesions, with an overall response rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33%, with responses being durable for 19+ months.
Final data on safety and efficacy, including overall survival (OS), will be presented at the Mini Oral presentation.
Immutep's share price is up 2.6% the past five days.